LOW-LEVEL LASER THERAPY FOR PAIN REDUCTION IN PSORIATIC ARTHRITIS: A RANDOMIZED CONTROLLED STUDY
Abstract
Background and Aims. Pain remains a dominant and disabling symptom in psoriatic arthritis (PsA), often persisting despite pharmacologic control of inflammation. Low-level laser therapy (LLLT) has emerged as a non-invasive modality with potential analgesic and anti-inflammatory effects. This study aimed to evaluate the efficacy of LLLT in reducing pain in patients with active PsA.
Methods. A randomized, double-blind, placebo-controlled trial included 117 PsA patients. Participants were assigned to active LLLT (n=59) or sham therapy (n=58), administered three times weekly for 8 weeks. Pain intensity was assessed using the visual analog scale (VAS). Secondary outcomes included Disease Activity Score in 28 joints (DAS28) and functional status. Statistical analysis included repeated-measures analysis and between-group comparisons.
Results. At baseline, pain levels were comparable between groups (VAS 62±15 vs. 65±18 mm; p>0.05). After 8 weeks, the LLLT group demonstrated a significantly greater reduction in pain (-42 mm vs. -15 mm; Δ = -27 mm; p < 0.0001; effect size g = 1.45), corresponding to a 68% decrease from baseline. Clinically meaningful pain reduction (≥20 mm) was achieved in 85% of LLLT patients compared to 30% in the placebo group (p < 0.001; relative risk = 2.83). Pain reduction correlated with improvement in disease activity (ρ=0.48; p=0.002), suggesting an inflammation-mediated mechanism. Repeated-measures analysis confirmed a significant group × time interaction (p < 0.001), indicating a sustained analgesic effect.
Conclusions. Low-level laser therapy provides significant and clinically meaningful pain reduction in PsA. It represents a safe and effective adjunctive strategy for managing persistent pain in inflammatory arthritis.
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2026 The Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.